COMPASS PATHWAYS Business Summary

Compass Pathways PLC (CMPS) is a clinical-stage biotechnology leader pioneering a proprietary model of psilocybin therapy, which integrates its synthetic psilocybin formulation, COMP360, with structured psychological support. The company currently generates no product revenue, operating as a research-intensive entity funded through equity offerings and strategic partnerships, with future monetization expected via direct product sales and licensing upon regulatory approval. Its primary business segments are centered on late-stage clinical development for Treatment-Resistant Depression (TRD), which is currently in Phase 3 trials, alongside secondary programs for Post-Traumatic Stress Disorder (PTSD) and anorexia nervosa. Within the competitive landscape, Compass Pathways maintains a first-mover advantage as the most advanced player in the psychedelic space, positioned ahead of direct rivals such as Cybin, MindMed, and Beckley Psytech, while differentiating itself from traditional pharmaceutical incumbents like Johnson & Johnson (Spravato) through its unique "drug-plus-therapy" delivery model. The company was founded in 2016 by George Goldsmith, Dr. Ekaterina Malievskaia, and Lars Christian Wilde, who sought to address systemic failures in mental health care. The current leadership team is headed by CEO Kabir Nath, former President of Otsuka’s North America Pharmaceutical Business, supported by CFO Teri Loxam (formerly of Gamut Capital and Merck) and Chief Medical Officer Dr. Guy Goodwin, a Professor Emeritus of Psychiatry at the University of Oxford. Other key executives include Chief Research and Development Officer Dr. Michael Gold and Chief Patient Officer Dr. Steve Levine. The company is backed by high-profile institutional investors, most notably Peter Thiel’s Founders Fund and ATAI Life Sciences, and is governed by a board chaired by Gino Santini, a veteran of Eli Lilly and Company.